ANAB is expected to report earnings to fall 84.85% to -27 cents per share on August 10
Q2'26
Est.
$-0.28
Q1'26
Missed
by $0.88
Q4'25
Beat
by $0.71
Q3'25
Beat
by $1.92
Q2'25
Beat
by $0.18
The last earnings report on May 12 showed earnings per share of -184 cents, missing the estimate of -95 cents. With 151.06K shares outstanding, the current market capitalization sits at 1.75B.
A.I. Advisor
published General Information
General Information
a provider of therapeutic antibodies for inflammation and immuno-oncology
A.I.dvisor indicates that over the last year, ANAB has been loosely correlated with CLRB. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ANAB jumps, then CLRB could also see price increases.
ANAB's RSI Indicator recovers from oversold territory
The RSI Indicator for ANAB moved out of oversold territory on June 08, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 12, 2026. You may want to consider a long position or call options on ANAB as a result. In of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on June 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .
ANAB moved above its 50-day moving average on June 18, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ANAB crossed bearishly below the 50-day moving average on June 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ANAB broke above its upper Bollinger Band on June 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ANAB entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (136.986) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). ANAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (7.305) is also within normal values, averaging (367.026).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
